Analysts Set Zura Bio Limited (NASDAQ:ZURA) PT at $14.33

Key Points

• Zura Bio Limited (NASDAQ:ZURA) has received a consensus rating of "Buy" from eight brokerage firms, with seven recommending a buy and one a strong buy.
• The average twelve-month price target for Zura Bio among analysts is $14.33, despite Oppenheimer adjusting their target price down from $19.00 to $17.00.
• The company's latest quarterly earnings report showed an EPS of ($0.19), falling short of the expected ($0.17) by $0.02.

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have earned an average rating of "Buy" from the eight analysts that are presently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.3333.

Separately, Oppenheimer dropped their price objective on Zura Bio from $19.00 to $17.00 and set an "outperform" rating for the company in a report on Friday, May 9th.

Hedge Funds Weigh In On Zura Bio

Hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC boosted its holdings in Zura Bio by 34.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company's stock worth $3,614,000 after acquiring an additional 723,933 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Zura Bio by 12,060.8% during the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock worth $6,583,000 after purchasing an additional 2,611,532 shares in the last quarter. Allostery Investments LP boosted its stake in shares of Zura Bio by 44.2% in the first quarter. Allostery Investments LP now owns 2,329,384 shares of the company's stock valued at $3,005,000 after purchasing an additional 714,258 shares during the period. Armistice Capital LLC boosted its stake in shares of Zura Bio by 2.4% in the first quarter. Armistice Capital LLC now owns 1,536,000 shares of the company's stock valued at $1,981,000 after purchasing an additional 36,000 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Zura Bio by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 955,426 shares of the company's stock valued at $2,389,000 after purchasing an additional 42,801 shares in the last quarter. Hedge funds and other institutional investors own 61.14% of the company's stock.

Zura Bio Stock Down 2.6%

Shares of ZURA stock traded down $0.04 during trading hours on Thursday, hitting $1.48. 170,876 shares of the company were exchanged, compared to its average volume of 898,305. The firm has a fifty day moving average of $1.32 and a 200 day moving average of $1.33. Zura Bio has a 1 year low of $0.97 and a 1 year high of $5.07. The firm has a market cap of $101.20 million, a PE ratio of -2.11 and a beta of -0.06.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). Analysts expect that Zura Bio will post -0.65 earnings per share for the current year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.